璞泰來(603659.SH)擬向子公司溧陽嘉拓劃轉3家子公司100%股權
格隆匯11月29日丨璞泰來(603659.SH)公佈,公司主營業務為鋰離子電池關鍵材料及自動化工藝設備的研發、生產和銷售,為適應未來鋰電設備業務的市場競爭環境,加強公司設備業務集中統一管理力度,公司擬調整設備業務管理體系。
公司以全資子公司溧陽嘉拓智能設備有限公司為平台,將公司直接持有的全資子公司深圳市新嘉拓自動化技術有限公司、寧德嘉拓智能設備有限公司、江西嘉拓智能設備有限公司100%股權按賬面淨值內部無償劃轉至溧陽嘉拓;本次劃轉完成後,深圳新嘉拓、寧德嘉拓、江西嘉拓將成為溧陽嘉拓的全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.